Study Highlights CyberKnife Stereotactic Body Radiotherapy (SBRT): Noninvasive Brachytherapy-like Treatment for Prostate Cancer
SUNNYVALE, Calif., Jan. 9, 2012 /PRNewswire/ – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced publication of a study describing the clinical outcomes of prostate cancer patients treated with stereotactic body radiotherapy (SBRT) using Accuray’s CyberKnife® Robotic Radiosurgery System in a manner that uniquely mimics HDR (high dose rate) brachytherapy dosing within the prostate gland. The University of California–San Francisco (UCSF) study, published in the January 2012 issue of the International Journal of Radiation Oncology – Biology – Physics (IJROBP) (commonly known as the Red Journal), employed a radiation dose scheme mimicking that of conventional invasive HDR brachytherapy to deliver high doses of radiation to regions of the prostate known to have a higher burden of prostate cancer cells instead of delivering a single uniform dose to the prostate. Patients with organ confined prostate cancer were treated in four short outpatient treatment sessions. Historically, HDR brachytherapy has been shown to be an effective treatment for prostate cancer, but requires the insertion of invasive catheters into the prostate making this treatment difficult for patients and technically challenging for physicians, limiting its widespread adoption. The CyberKnife System is able to easily and quickly mimic this proven treatment in a noninvasive manner because of its ability to easily create and paint complex doses within the prostate.
The study, “Stereotactic Body Radiotherapy as Monotherapy or Post-External Beam Radiotherapy Boost for Prostate Cancer: Technique, Early Toxicity, and PSA Response,” reported on 38 patients ranging in age from 54 to 82 years with a minimum follow-up of 12 months. Twenty of the 38 patients were treated with CyberKnife SBRT monotherapy and 18 were treated with CyberKnife SBRT boost following external beam radiotherapy (EBRT). The research found that CyberKnife SBRT was well tolerated and after a median follow-up of 18.3 months, reported progression free survival was 100 percent.
“This UCSF study is one of the first to document clinical outcomes of CyberKnife HDR-like SBRT for prostate cancer. The results are encouraging, especially when compared to historic experience for invasive HDR brachytherapy for patients with prostate cancer,” said Siavash Jabbari, M.D., lead author of the UCSF study, currently a radiation oncologist at Advocate Lutheran General Hospital, Park Ridge, IL. “The CyberKnife System enables us to replicate HDR brachytherapy dosimetry and these early results suggest that we are able to achieve excellent clinical outcomes without the invasiveness and disadvantages of HDR brachytherapy. We look forward to continuing to follow these patients and the development of long term clinical data for this treatment option for prostate cancer.”
Prostate SBRT is a challenging treatment that requires high degrees of accuracy and precision and the ability to actively track and correct for prostate motion during treatment. The UCSF study describes the next evolution in prostate SBRT by dose painting regions of the prostate with high doses of radiation to maximize clinical outcomes, while limiting dose to organs such the urethra, bladder, and rectum. The creation of these very high dose regions during a prostate SBRT course is enabled by the CyberKnife System’s ability to sculpt dose and create complex dosing schemes to match the optimal clinical objectives for a patient. Unlike other SBRT technologies, the CyberKnife System’s robotic capabilities allow it to make active corrections for prostate motion during treatment, enabling clinicians to confidently deliver prostate SBRT while sparing the surrounding critical tissues.
In addition to the publication of the UCSF study in December, the second of two, multi-center Accuray sponsored CyberKnife prostate SBRT clinical studies, which focused specifically on prostate cancer patients treated with CyberKnife SBRT with HDR like dosing, completed accrual. This multi-center prospective study involving 19 centers was lead by Dr. Donald Fuller of the CyberKnife Centers of San Diego and completed patient accrual this past month with treatment of 253 patients who are now in follow-up. This study, along with the other Accuray sponsored CyberKnife prostate SBRT multi-center study led by Swedish Cancer Center in Seattle, create the largest multi-center clinical experience for prostate SBRT to date and will serve as a strong foundation to support the long term clinical benefits and differentiation of the CyberKnife system in delivering prostate SBRT.
“We are very excited to see the clinical evidence for CyberKnife prostate SBRT maturing and the long term benefits of these treatments supported by high quality clinical research,” said Omar Dawood, M.D., M.P.H., vice president of global medical affairs for Accuray. “The CyberKnife System’s ability to accurately paint high doses of radiation selectively to focal areas within the prostate highlights the clinical benefits of having a robotic system that is specifically designed for radiosurgery and SBRT. This unique approach to prostate SBRT may help to further revolutionize this field and provide increasing benefits for patients.”
Click here to see a patient education video about how prostate cancer is treated with the CyberKnife System.
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company’s leading edge technologies – the CyberKnife and TomoTherapy Systems – are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date, more than 200,000 patients worldwide have been treated using the Company’s technologies and more than 598 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to types of patient treatments, clinical objectives, and clinical benefits are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: treatment options, clinical experience, clinical applications, and clinical effectiveness and other risks detailed from time to time under the heading “Risk Factors” in our report on Form 10-K for our 2011 fiscal year, our form 10-Q filed on November 8, 2011 and our other filings with the Securities and Exchange Commission. The Company’s actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
Euan Thomson, Ph.D.
SOURCE Accuray Incorporated